TP53 alterations have been reported in 29–80% of ovarian tumors, with a higher incidence in high-grade pelvic (primary ovarian, tubal, or peritoneal) serous carcinoma (91–97%) (33). Here, TP53 is linked to serous adenocarcinoma.